Two out of the three major indices traded up today The three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 22 points (0.1%) at 17,430 as of Friday, Aug. 14, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,691 issues advancing vs. 1,250 declining with 211 unchanged.

The Chemicals industry as a whole closed the day up 0.3% versus the S&P 500, which was up 0.2%. Top gainers within the Chemicals industry included Marrone Bio Innovations ( MBII), up 9.6%, Arcadia Biosciences ( RKDA), up 7.1%, Synthesis Energy Sys ( SYMX), up 1.9%, Lightbridge ( LTBR), up 3.0% and Amyris ( AMRS), up 1.8%.

TheStreet Ratings Group would like to highlight 3 stocks pushing the industry higher today:

Synthesis Energy Sys ( SYMX) is one of the companies that pushed the Chemicals industry higher today. Synthesis Energy Sys was up $0.02 (1.9%) to $1.06 on light volume. Throughout the day, 230,477 shares of Synthesis Energy Sys exchanged hands as compared to its average daily volume of 504,100 shares. The stock ranged in a price between $1.01-$1.08 after having opened the day at $1.06 as compared to the previous trading day's close of $1.04.

Synthesis Energy Systems, Inc., a development stage energy and gasification technology company, provides various proprietary gasification technology systems and solutions to the energy and chemical industries worldwide. Synthesis Energy Sys has a market cap of $84.4 million and is part of the basic materials sector. Shares are up 9.8% year-to-date as of the close of trading on Thursday. Currently there are no analysts who rate Synthesis Energy Sys a buy, no analysts rate it a sell, and none rate it a hold.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreet Ratings rates Synthesis Energy Sys as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and generally disappointing historical performance in the stock itself.

Highlights from TheStreet Ratings analysis on SYMX go as follows:

  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Energy Equipment & Services industry and the overall market, SYNTHESIS ENERGY SYSTEMS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • SYMX has underperformed the S&P 500 Index, declining 7.57% from its price level of one year ago. The fact that the stock is now selling for less than others in its industry in relation to its current earnings is not reason enough to justify a buy rating at this time.
  • SYMX, with its very weak revenue results, has greatly underperformed against the industry average of 22.4%. Since the same quarter one year prior, revenues plummeted by 61.4%. The declining revenue has not hurt the company's bottom line, with increasing earnings per share.
  • SYMX's debt-to-equity ratio is very low at 0.13 and is currently below that of the industry average, implying that there has been very successful management of debt levels. Although the company had a strong debt-to-equity ratio, its quick ratio of 0.94 is somewhat weak and could be cause for future problems.
  • SYNTHESIS ENERGY SYSTEMS INC has improved earnings per share by 16.7% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. During the past fiscal year, SYNTHESIS ENERGY SYSTEMS INC continued to lose money by earning -$0.21 versus -$0.34 in the prior year.

You can view the full analysis from the report here: Synthesis Energy Sys Ratings Report

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

At the close, Arcadia Biosciences ( RKDA) was up $0.31 (7.1%) to $4.69 on light volume. Throughout the day, 16,358 shares of Arcadia Biosciences exchanged hands as compared to its average daily volume of 77,100 shares. The stock ranged in a price between $4.37-$4.70 after having opened the day at $4.37 as compared to the previous trading day's close of $4.38.

Arcadia Biosciences has a market cap of $190.5 million and is part of the basic materials sector. Shares are unchanged year-to-date as of the close of trading on Thursday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Marrone Bio Innovations ( MBII) was another company that pushed the Chemicals industry higher today. Marrone Bio Innovations was up $0.17 (9.6%) to $1.95 on light volume. Throughout the day, 32,444 shares of Marrone Bio Innovations exchanged hands as compared to its average daily volume of 142,000 shares. The stock ranged in a price between $1.76-$1.96 after having opened the day at $1.80 as compared to the previous trading day's close of $1.78.

Marrone Bio Innovations, Inc. provides bio-based pest management and plant health products for the crop protection, water treatment, and other target markets in the United States and internationally. Marrone Bio Innovations has a market cap of $45.6 million and is part of the basic materials sector. Shares are down 50.7% year-to-date as of the close of trading on Thursday. Currently there are no analysts who rate Marrone Bio Innovations a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Marrone Bio Innovations as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share and deteriorating net income.

Highlights from TheStreet Ratings analysis on MBII go as follows:

  • MARRONE BIO INNOVTIONS has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. For the next year, the market is expecting a contraction of 86.2% in earnings (-$1.75 versus -$0.94).
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Chemicals industry. The net income has significantly decreased by 533.6% when compared to the same quarter one year ago, falling from -$1.64 million to -$10.39 million.
  • MBII, with its decline in revenue, slightly underperformed the industry average of 10.9%. Since the same quarter one year prior, revenues fell by 19.4%. Weakness in the company's revenue seems to have hurt the bottom line, decreasing earnings per share.
  • Compared to other companies in the Chemicals industry and the overall market, MARRONE BIO INNOVTIONS's return on equity significantly trails that of both the industry average and the S&P 500.
  • Despite any intermediate fluctuations, we have only bad news to report on this stock's performance over the last year: it has tumbled by 80.52%, worse than the S&P 500's performance. Consistent with the plunge in the stock price, the company's earnings per share are down 455.55% compared to the year-earlier quarter.

You can view the full analysis from the report here: Marrone Bio Innovations Ratings Report

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.